Dengue Cases Surge to Over 50,000 in Sri Lanka with 30 Deaths Reported

Lipoprotein(a), commonly abbreviated as Lp(a), is a type of lipoprotein particle found in the blood that has gained increasing attention in cardiovascular health assessment. This particle consists of a low-density lipoprotein (LDL) core attached to a unique protein called apolipoprotein(a). Unlike other cholesterol markers that can be modified through diet and lifestyle changes, Lp(a) levels are primarily determined by genetics and remain relatively stable throughout a person's lifetime. Elevated levels of Lp(a) are recognized as an independent risk factor for cardiovascular diseases, including heart attacks, strokes, and aortic valve stenosis.

Testing for Lp(a) is particularly valuable for individuals with a family history of early heart disease, those who have experienced cardiovascular events despite normal cholesterol levels, or people with recurring cardiovascular problems despite treatment. The test is performed using a blood sample, typically drawn from a vein in the arm. Since Lp(a) levels are genetically determined and do not fluctuate significantly with fasting status, the test can usually be performed without special preparation, though some laboratories may request fasting for consistency with other lipid panel tests.

Normal Lp(a) levels are generally considered to be below 30 milligrams per deciliter (mg/dL) or less than 75 nanomoles per liter (nmol/L), though optimal levels may be even lower. Levels above 50 mg/dL are associated with increased cardiovascular risk, and the risk continues to rise with higher concentrations. It is important to note that reference ranges may vary slightly between laboratories due to different testing methods and measurement units. Unlike LDL cholesterol or triglycerides, Lp(a) levels do not respond well to standard lifestyle modifications such as diet, exercise, or most cholesterol-lowering medications.

When Lp(a) levels are found to be elevated, healthcare providers typically focus on aggressively managing other modifiable cardiovascular risk factors. This may include optimizing LDL cholesterol levels, controlling blood pressure, managing diabetes if present, encouraging smoking cessation, and promoting regular physical activity. Some specialized treatments, including certain lipid-lowering therapies and emerging medications specifically targeting Lp(a), may be considered in high-risk individuals. Regular monitoring and comprehensive cardiovascular risk assessment become especially important for those with elevated Lp(a) levels to prevent future cardiovascular events.